Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McMaster University

$27,000.00

Interferon lambda as a novel anti-inflammatory modulator of the skin barrier-immune-microbiome axis in atopic dermatitis

FY 2025-26

Summary
This project will investigate interferon-lambda (IFN-L) as a multi-target therapy for atopic dermatitis (AD), a common inflammatory skin disease. AD develops from disruption across three interconnected features: a weakened skin barrier, an overactive immune response, and an imbalance in healthy skin bacteria. When any of these systems becomes disturbed, they reinforce one another and create a persistent cycle of inflammation characterized by skin irritation, redness, and lesions. Existing treatments can reduce short-term inflammation, but they generally target only one part of this cycle. As a result, many patients continue to experience recurrent flares and limited long-term symptom control. The signalling protein, IFN-L, is a promising therapeutic candidate because it mainly acts on barrier tissues such as the skin. Early studies suggest it can strengthen barrier structure, limit immune activation, and reduce harmful bacteria while avoiding widespread inflammation. This means that IFN-L may address several root causes of AD rather than treating symptoms alone. In this study, we will test IFN-L in a mouse model that closely reflects human AD. We will assess whether IFN-L improves skin structure, reduces immune signalling, and restores a healthier balance of skin bacteria by comparing IFN-L-treated mice with controls. Demonstrating improvements across these features would provide the first comprehensive evidence supporting IFN-L as a multi-target therapy for AD. Ultimately, this work may contribute to the development of more effective treatments that reduce flares, prevent severe symptoms, and improve overall quality of life for individuals living with chronic AD.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
573022
Name
Read Maddie L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Interferon lambda as a novel anti-inflammatory modulator of the skin barrier-immune-microbiome axis in atopic dermatitis
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Anti-Inflammatory Therapeutics; Atopic Dermatitis; Cytokines; Epidermal Barriers; Epithelial Tissues; Immune Dysregulation; Immunotherapy; Inflammation; Skin Immunology; Skin Microbiota
Abstract
This project will investigate interferon-lambda (IFN-L) as a multi-target therapy for atopic dermatitis (AD), a common inflammatory skin disease. AD develops from disruption across three interconnected features: a weakened skin barrier, an overactive immune response, and an imbalance in healthy skin bacteria. When any of these systems becomes disturbed, they reinforce one another and create a persistent cycle of inflammation characterized by skin irritation, redness, and lesions. Existing treatments can reduce short-term inflammation, but they generally target only one part of this cycle. As a result, many patients continue to experience recurrent flares and limited long-term symptom control. The signalling protein, IFN-L, is a promising therapeutic candidate because it mainly acts on barrier tissues such as the skin. Early studies suggest it can strengthen barrier structure, limit immune activation, and reduce harmful bacteria while avoiding widespread inflammation. This means that IFN-L may address several root causes of AD rather than treating symptoms alone. In this study, we will test IFN-L in a mouse model that closely reflects human AD. We will assess whether IFN-L improves skin structure, reduces immune signalling, and restores a healthier balance of skin bacteria by comparing IFN-L-treated mice with controls. Demonstrating improvements across these features would provide the first comprehensive evidence supporting IFN-L as a multi-target therapy for AD. Ultimately, this work may contribute to the development of more effective treatments that reduce flares, prevent severe symptoms, and improve overall quality of life for individuals living with chronic AD.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Read, Maddie L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~